Article information
Resumen
Las novedades presentadas en la semana de enfermedades digestivas de este año sobre reflujo gastroesofágico tienen especial relevancia práctica. Los resultados a 5 años de un estudio aleatorizado multicéntrico —el estudio LOTUS— demuestran que los inhibidores de la bomba de protones son superiores a la cirugía en el tratamiento de los pacientes con reflujo. Por otro lado, nuevos estudios rescatan del olvido las medidas higienicodietéticas en el tratamiento del reflujo, demostrando que la pérdida de peso y dejar de fumar mejoran los síntomas del reflujo de manera espectacular. Respecto al esófago de Barrett, se confirma no sólo la eficacia a corto plazo del tratamiento con radiofrecuencia en pacientes con displasia, sino que empiezan a aparecer datos muy favorables sobre su eficacia a largo plazo.
Palabras clave:
Reflujo gastroesofágico
Diagnóstico
Tratamiento
Esófago de Barrett
Abstract
The advances presented in Digestive Disease Week 2010 on gastroesophageal reflux disease are of special practical importance. The 5-year results of a randomized, multicenter trial —the LOTUS trial— show that proton pump inhibitors are superior to surgery in the treatment of patients with reflux. In addition, new studies have rescued hygienic-dietary measures from oblivion in the treatment of reflux, showing that weight loss and smoking cessation spectacularly improve symptoms. In Barrett's esophagus, the short-term efficacy of radiofrequency in patients with dysplasia has been confirmed and highly encouraging data on the long-term efficacy of this treatment modality have begun to appear.
Keywords:
Gastroesophageal reflux disease
Diagnostic
Treatment
Barret esophagus
Full text is only aviable in PDF
Bibliografía
[1.]
E. Savarino, P. Zentilin, M. Frazzoni, E. Marabotto, G. Sammito, L. Gemignani, et al.
Functional heartburn and non-erosive reflux disease: the added value of impedance-ph monitoring to ROME III criteria.
Gastroenterology, 138 (2010), pp. S491
[2.]
J.P. Galmiche, J.G. Hatlebakk, S.E. Attwood, C. Ell, R. Fiocca, S. Eklund, et al.
Laparoscopic antireflux surgery vs long-term esomeprazole treatment for chronic GERD. Final results after 5 yrs of follow up in the Lotus Study.
Gastroenterology, 138 (2010), pp. S53
[3.]
C. Ell, L. Lundell, C.M. Seiler, J.P. Galmiche, R. Fiocca, J.G. Hatlebakk, et al.
Safety profile in GERD patients 5 yrs after laparoscopic antireflux surgery or long-term treatment with esomeprazole 20-40mg daily in the Lotus Study.
Gastroenterology, 138 (2010), pp. S654
[4.]
M. Singh, J. Lee, A. Bansal, D.K. Sullivan, B.K. Smith, J.E. Donnelly, et al.
Weight loss can lead to complete resolution of GERD symptoms: a prospective study.
Gastroenterology, 138 (2010), pp. S135
[5.]
M.D. Crowell, R.L. Levy, J.K. DiBaise, R.W. Jeffery.
Symptomatic improvement in gastroesophageal reflux disease (GERD) following weight loss through caloric restriction and behavioral modification.
Gastroenterology, 138 (2010), pp. S646
[6.]
T. Xenodemetropoulos, K.J. Khan, G.I. Leontiadis, D. Armstrong, D. Moayyedi.
The gamma-aminobutyric acid (GABA) receptor agonist baclofen in the treatment of gastroesophageal reflux disease (GERD): A systematic review.
Gastroenterology, 138 (2010), pp. S650
[7.]
S. Bruley des Varennes, R. Tutuian, S. Roman, F. Zerbib, F. Mion, J.F. Tack, et al.
Effect of a mGluR5 negative allosteric modulator (NAM) ADX10059 monotherapy on reflux events and lower esophageal sphincter (LES) function in patients with gastroesophageal reflux disease (GERD).
Gastroenterology, 138 (2010), pp. S135
[8.]
F. Zerbib, J.P. Galmiche, F. Mion, C. Keywood.
Clinical efficacy and tolerability of monotherapy with ADX10059, a mGluR5 negative allosteric modulator for symptom control in patients with gastro- esophageal reflux disease (GERD).
Gastroenterology, 138 (2010), pp. S648
[9.]
W.W. Chan, E. Chiou, K.L. Obstein, A.S. Tignor, T.L. Whitlock.
The efficacy of proton pump inhibitors for treatment of asthma: a meta-analysis.
Gastroenterology, 138 (2010), pp. S644
[10.]
A. Bansal, M. Singh, O. Anand, D.H. McGregor, P.G. Jones, R. Cherian, et al.
Comparative study of dysplasia and cancer risk in intestinal metaplasia (IM) and non-intestinal metaplasia epithelia: clinical implications for the definition of Barrett's esophagus.
Gastroenterology, 138 (2010), pp. S2
[11.]
K.W. Jung, K.T. Dunagan, M. Fredericksen, D.M. Geno, Y. Romero, K.K. Wang, et al.
Natural history of intestinal metaplasia of the gastroesophageal junction in Olmsted County, MN: a population based cohort study.
Gastrointestinal Endoscopy, 71 (2010), pp. AB121
[12.]
C.M. Den Hoed, B.C. Van Eijck, P.D. Siersema, E.J. Kuipers.
Prevalence of esophagitis and Barrett's esophagus patients undergoing routine colonoscopy; a cohort study.
Gastroenterology, 138 (2010), pp. S332
[13.]
B. Lindkvist, W. Borena, T. Björge, T. Stocks, H. Jonsson, J. Manjer.
Metabolic factors and the risk for adenocarcinoma and squamous cell carcinoma of the esophagus. A prospective analysis of 570,000 subjects within the metabolic syndrome and cancer project (Me-Can).
Gastroenterology, 138 (2010), pp. S290
[14.]
F. Yousef, S. Bhat, H.G. Mulholland, D.T. McManus, B.T. Johnston, A.T. Gavin, et al.
Low incidence of esophageal adenocarcinoma in Barrett's esophagus: time to rethink surveillance guidelines?.
Gastroenterology, 138 (2010), pp. S16
[15.]
S.B. Wani, G.W. Falk, M. Hall, A. Wang, N. Gupta, M. Singh, et al.
Low risk of developing dysplasia and esophageal adenocarcinoma (EAC) in patients with non-dysplastic Barrett's esophagus (BE): results from a large, multicenter, cohort study.
Gastroenterology, 138 (2010), pp. S63
[16.]
D.A. Corley, K. Mehtani, W. Zhao, J. DeBoer, N. Weiss, A. Kubo.
Barrett's esophagus surveillance and risk of death from esophageal adenocarcinoma: a case-control study.
Gastroenterology, 138 (2010), pp. S16
[17.]
N.I. Okoro, G.A. Prasad, Y. Tomizawa, V. Namasivayam, N. Buttar, K.T. Dunagan, et al.
Is biopsy necessary in narrow band imaging (NBI) negative patients?.
Gastrointestinal Endoscopy, 71 (2010), pp. AB122
[18.]
W.L. Curvers, F.G. Van, B.C. Baak, C. Bohmer, R.C. Mallant-Hent Arnoud, H. Van Oijen, et al.
A multi-centre randomized cross-over trial comparing endoscopic tri-modal imaging (ETMI) with standard endoscopy (SE) for the detection of dysplasia in Barrett's esophagus (BE) patients with confirmed LGD performed in a non-university setting.
Gastroenterology, 138 (2010), pp. S155
[19.]
S. Gaddam, P.E. Young, A. Wang, A. Bansal, N. Gupta, S.B. Wani, et al.
Predicting high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with non-dysplastic Barrett's esophagus (BE): results from a large, multicenter cohort study.
Gastroenterology, 138 (2010), pp. S333
[20.]
R.E. Pouw, R. Bisschops, O. Pech, K. Ragunath, B.L. Weusten, B. Schumacher, et al.
Safety outcomes of balloon-based circumferential radiofrequency ablation after focal endoscopic resection of early Barrett's neoplasia in 118 patients: results of an ongoing European multicenter study.
Gastrointestinal Endoscopy, 71 (2010), pp. AB126
[21.]
P.H. Deprez, H. Piessevaux, T. Aouattah, R.C. Yeung, C. Sempoux, A. Jouret.
ESD in Barrett's esophagus high grade dysplasia and mucosal cancer: prospective comparison with CAP mucosectomy.
Gastrointestinal Endoscopy, 71 (2010), pp. AB126
[22.]
A. Moss, M.J. Bourke, L.F. Hourigan, R.G. Walker, S. Gupta, A.J. Metz, et al.
Complete Barrett's excision (CBE) by endoscopic resection (ER): a highly effective and durable curative option for Barrett's segments with high grade dysplasia (HGD) or early adenocarcinoma (EAC).
Gastrointestinal Endoscopy, 71 (2010), pp. AB127
[23.]
N.J. Shaheen, D.E. Fleischer, G.M. Eisen, K.K. Wang, A.F. Peery, A. Infantolino, et al.
Durability of epithelial reversion after radiofrequency ablation: follow-up of the AIM Dysplasia Trial.
Gastroenterology, 138 (2010), pp. S16
[24.]
D.E. Fleischer, B.F. Overholt, V.K. Sharma, A. Reymunde, M.B. Kimmey, R. Chuttani, et al.
Endoscopic radiofrequency ablation for Barrett's esophagus: five-year durability outcomes from a prospective multi-center trial.
Gastrointestinal Endoscopy, 71 (2010), pp. AB117-AB118
[25.]
S.B. Wani, N. Gupta, B. Domit, K.Y. Chuang, S. Gaddam, V. Singh, et al.
Durability of ablative therapies in Barrett's esophagus (BE): long term results of a randomized controlled trial (RCT) of ablation with argon plasma coagulation (APC) and multipolar electrocoagulation (MPEC).
Gastroenterology, 138 (2010), pp. S333
[26.]
J. Bergman, D.E. Fleischer, Z. Yueming, S.M. Dawsey, L. Ning, B.L. Weusten, et al.
First prospective study on endoscopic radiofrequency ablation of moderate and high-grade intraepithelial squamous neoplasia and early squamous cell cancer of the esophagus.
Gastrointestinal Endoscopy, 71 (2010), pp. AB126-AB127
[27.]
F.G. Van, L. Álvarez Herrero, R.E. Pouw, C. Sondermeijer, J. Fiebo, T. Kate, et al.
A Pilot trial of endoscopic radiofrequency ablation for the eradication of esophageal squamous intraepithelial neoplasia and early squamous cell carcinoma limited to the mucosa.
Gastroenterology, 138 (2010), pp. S863
[28.]
J. Molina, L. Ferrando, B. Pérez Gallardo, G. Vinagre Rodríguez, M. Hernández Alonso, C. Dueñas, et al.
Systematic clinicopathological follow-up on high-dose acid suppression is mandatory to avoid eosinophilic esophagitis overestimation in adults.
Gastroenterology, 138 (2010), pp. S173
[29.]
G.T. Furuta, C.A. Liacouras, M.H. Collins, S.K. Gupta, C. Justinich, P.E. Putnam, et al.
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment.
Gastroenterology, 133 (2007), pp. 1342-1363
[30.]
R. Dohil, R. Newbury, L. Fox, J.F. Bastian, S. Aceves.
A randomized, double-blind, placebo-controlled study of oral viscous budesonide (OVB) in children with eosinophilic esophagitis (EoE).
Gastroenterology, 138 (2010), pp. S62
[31.]
K. Wook Jung, N. Gundersen, A.S. Arora, Y. Romero, D.L. Francis, A. Julie, et al.
Complications after endoscopic dilation in eosinophilic esophagitis and associated risk factors.
Gastrointestinal Endoscopy, 71 (2010), pp. AB138
Copyright © 2011. Elsevier España S.L.. Todos los derechos reservados
